Stockreport

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF Highly statistically significant results on all primary and secondary endpointsStatistical significance seen as early as day 28, after 4 weeks of treatment in WART-203If [Read more]